Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Palisade Capital Management LP

Palisade Capital Management LP raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 1.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 200,972 shares of the company's stock after purchasing an additional 3,676 shares during the quarter. Palisade Capital Management LP's holdings in Novo Nordisk A/S were worth $13,955,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in NVO. Victory Capital Management Inc. increased its position in shares of Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after acquiring an additional 23,223 shares during the period. North Star Investment Management Corp. boosted its holdings in shares of Novo Nordisk A/S by 18.2% in the 1st quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after buying an additional 3,200 shares in the last quarter. Stanley Laman Group Ltd. purchased a new position in shares of Novo Nordisk A/S during the first quarter worth about $390,000. Dover Advisors LLC purchased a new position in Novo Nordisk A/S during the 1st quarter worth approximately $505,000. Finally, Natural Investments LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $1,345,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the subject of a number of research reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded down $0.77 during trading hours on Friday, hitting $69.05. The company's stock had a trading volume of 4,047,911 shares, compared to its average volume of 7,246,407. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The business has a fifty day moving average of $69.82 and a 200-day moving average of $76.19. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $143.69. The stock has a market cap of $308.31 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 1.36 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.